Pharmacy has a long history of providing products and services for healthcare. In the last century, these roles have taken a strong focus on clinical care with the provision of medicines review, medicines optimisation, and prescribing services being at the forefront. The profession, however, is diverse. Pharmacists operate across a wide range of healthcare practices that often embrace both historic and contemporary roles simultaneously. The purpose of this article is to provide an overarching philosophical framework for pharmacy that encompasses roles that the modern pharmacist may assume. In doing this, we explore how pharmacy services align with healthcare and how different services require different approaches to clinical decision making.
Introduction
The role of the modern pharmacist in healthcare can be traced back over several centuries and stems from the apothecary. 1 An apothecary was a practitioner who examined patients, prescribed treatments for illnesses, and compounded medicines for sale. The sale generated the revenue for the consultation. In the 1800s, the apothecary role split to form what we now know as the modern family doctor and pharmacist. While some roles of both the apothecary and modern pharmacist remain consistent today, such as purveying medical products, many roles have extended the historic scope far beyond that of the past. In the 21st Century, pharmacists perform fee-for-clinical service roles, such as prescribing and medicines optimisation, as well as acting as advisors to physicians, patients, and other healthcare providers about the optimal use of medicines. As modern drug treatments have become more complex, so has the role that pharmacists play in ensuring their safe and effective use. It is important to note that the profession of pharmacy has not become complex as a function of what it seeks to achieve in terms of patient care, but rather as a function of how it provides its expertise, and, to a certain extent, as a function of who receives this expert service. For pharmacy, what we seek to achieve, better health outcomes for our communities, remains consistent with the past. However, how we achieve this outcome in the 21st Century, perhaps by optimising medicines usage, is often neither clear nor transparent to the lay public. The layperson, while central to our professional goals, is often not a physical participant in our professional activities. For instance, during a consultation with a pharmacist, the person may not be manipulated physically as during a consultation with the family doctor or physiotherapist. Instead, the pharmacist will often perform key professional functions tacitly. The pharmacist will apply in-depth reasoning processes while in conversation with the person or at some stage after the formal interview is concluded. While the pharmacist will work with the patient and their goals, the primary recipient of the pharmacist's knowledge and skill will often culminate in a set of recommendations regarding a treatment plan for the prescriber, rather than the person. The outcome of the professional activity, therefore, may not be obvious to the person. In this context, there is a potential danger that the pharmacy profession may be perceived by the lay public, and other health professionals, as a silent partner in healthcare and, as such, reinforce a possible belief that it does not contribute greatly to health outcomes. This paper proposes a philosophical framework to encompass the what (goal of pharmacy practice) and how (methods used by pharmacists to achieve their goals) for the pharmacy profession in the 21st century. This framework should provide a basis for discussion and thinking about how pharmacists define their professional service roles and how we design education programmes to train future pharmacists. It will first define the professional roles of pharmacy and develop a conceptual outline of the clinical decision making processes that lie at the heart of these activities. It will then propose that the professional activities of modern pharmacy practice are linked philosophically to the principles of bioethics, primarily beneficence (to do good) and non-maleficence (to not do harm). It is observed that most traditional professional activities for pharmacy are underpinned by a non-maleficent approach while the recent move towards expanded clinical services are underpinned by a beneficent focus. The paper concludes by proposing how the profession achieves its goals, the skills required, and the educational underpinnings, will be fundamentally different given its philosophical orientation.
In this work, the authors do not interrogate the who (the "patient", "healthcare partner", "health service purchaser"), other than to highlight that the person is integral to the healthcare process and that this includes the clinical decision making process.
This paper does not attempt to survey the tasks and duties that are performed by pharmacists. There is a wide-ranging literature that shows health benefits in terms of access to medicines (such as provision of vaccines 2, 3 ), quality of medicines (such as cold chain 4 ) and quality use of medicines. 5 It does not advocate or promulgate the need, or otherwise, for change. Rather, it suggests a framework to accommodate current and future changes in the profession. This framework is intended to create a foundation for the profession to acknowledge the varied roles pharmacists are now performing in their practice.
The professional role of pharmacy
Traditionally, an apothecary was a conglomerate of healthcare practitioners, including pharmacist and family doctor. 1 They relied on the sale of medicines to compensate for provision of healthcare services rather than directly charging, or otherwise being compensated, on a fee-for-service basis. In this sense, the balance of needing to maintain a sustainable business by sale versus meeting the health needs of the patient, who may not need a product, would represent an ongoing conflict of interest. Despite this apparent conflict, the apothecary was able to provide affordable healthcare to their communities. 1 While, in the 1800s medical practitioners broke away from this model towards a solely fee-for-service, pharmacists have maintained a mixed model of fee-for-product and fee-for-service. The main change in the role of the modern pharmacist has been a move away from the provision of bespoke manufactured products to provision of clinical care. Fig. 1 depicts a schematic of the transitions in the pharmacy profession. The four transition states are (1) manufacturer and purveyor of medicinal products, (2) dispenser and manufacturer, (3) dispenser and clinical checker and (4) clinical service provider. The first three roles are defined by a fee-forproduct whereas the fourth role represents a fee-for-service. The fourth role here is further subdivided into medicines optimisation, and prescribing. The central premise in the clinical checking and clinical service roles lies in the enactment of a clinical decision aimed at promoting healthcare. This contrasts with a role-based around safe preparation of a product. In this schematic, the span of roles is greater in the 21st century than previously. The greater span of roles indicates that the addition of new services has begun prior to the demise of older services. This paper focuses on the role of the pharmacist in clinical care which is driven by clinical decision making.
Clinical decision making
Clinical decision making, like all decision making, is a formal process that defines the way a practitioner arrives at a decision from the information at hand. Generically, decision making has been described as a 7-step process [http://www.umassd.edu/fycm/ decisionmaking/process/]: (1) identifying the need for a decision, (2) gathering information, (3) identifying alternatives, (4) weighing the evidence, (5) choosing among alternatives, (6) take action and (7) reviewing the decision. The authors herein describe a simpler process consisting of information gathering followed by a threestage process comprising reasoning, judging, and deciding. This approach delineates pre-decision components (i.e. which include workup of the patient and orientation to patient goals) and postdecision components (i.e. developing reasoning, developing and enacting a clinical decision with the patient and evaluating feedback from patient outcomes). The three steps of clinical decision making in Fig. 2 map directly onto items 3, 4 and 5 of a standard decision making model. Finally, it is noted that patient outcomes are monitored and provide further information in a decision making cycle. This is implicit in the approach taken here. Showing the components linearly helps to signify the start and finish of an individual decision making cycle.
While the schematic in Fig. 2 can be applied directly to healthcare decisions, it is important to note that the healthcare decision making process is inherently complex. Typically, decisions are based on many factors including those relating to the history and goals of the patient and family, the current evidence base for medicine effectiveness, the pharmacological and pharmaceutical implications of the drug and product, societal expectations and constraints, and the ability of the practitioner to arrive at, communicate and negotiate the decision. In order to represent this Fig. 1 . This timeline depicts the key roles of pharmacists over the last half millennium. Starting in the role of apothecary (from the 1600s), the blue shade denotes manufacturing and selling products, the green signifying dispensing against a physician order, gold the advent of clinical checking (an additional clinical safety check linked to the dispensing service), and the red and pink represent the provision of fee for service clinical service. The red denotes medicines optimisation services and the pink prescribing. complexity, we have expanded Fig. 2 as a representative illustration (see Fig. 3 ). In this schematic, we have omitted pre-clinical decision making components. This renders a decision making model where there are a potentially large number of factors (denoted n) that form the basis of reasoning each of which yields a judgement. Each of these individual judgements are then weighed again to form an overall judgement of the best action. This judgement forms the basis of a decision enacted, such as optimising the choices of medicines for a patient. It is noted that while it is possible to display a schematic of (almost) infinite complexity, it is likely that the expert practitioner will not necessarily consider every item but rather limit the field by lumping and splitting factors to a reasonable selection of items. 6 
A philosophical framework to underpin professional pharmacy practice
Pharmacy practice currently lacks a philosophical framework that links the changing professional activities undertaken by pharmacists and the decision making processes that are required to undertake these roles. Our primary function in the health-care system has rapidly evolved from purveyors of medical products and clinical checkers to an active involvement in shaping patients' treatment plans. We propose that the professional activities of modern pharmacy practice can be linked philosophically to the foundational principles of bioethics as indeed can all professions (i.e. these principles are not unique to pharmacy). The four commonly cited cornerstones of bioethics are beneficence (to do good), non-maleficence (to avoid doing bad), justice (equality of healthcare for all) and autonomy (patient choice) 7 , see also the and also the work of Kelling 8 in reviewing the bioethical principles of medicines related services of pharmacists. This paper considers only beneficence and non-maleficence. This is not to reduce or marginalise the other cornerstones but rather allows discussion to focus on how the two principles link to the pharmacist's role in clinical care and clinical decision making. The role of pharmacists naturally align with beneficent and nonmaleficent activities. For the purpose of this work, we subdivide beneficence into primary and secondary beneficence. Primary beneficence refers to a decision of a practitioner that was selfinitiated, i.e. the practitioner initiated the decision making process (as per Fig. 3) . A typical example might be a prescribing pharmacist or medical practitioner diagnosing and initiating treatment of a condition. Secondary beneficence refers to a decision of a second practitioner that is intended to influence the decision of the initiating (primary beneficent) practitioner. The latter description is akin to a practitioner who provides advice to help in the clinical reasoning process of another, for instance a pharmacist may contact a prescriber about a clinical concern and provide advice intended to improve health outcomes in the patient.
Pharmacists as the non-maleficent practitioner
When in a non-maleficent role, the pharmacist's primary goal Fig. 2 . This schematic identifies the main processes that underpin decision making. These are Reasoning, which is predicated on health information (i.e. a function of patient related factors and evidence based practice), Judgement, where the Reasoning is weighted according to the risk and benefits that underpin the reasoning. The Judgement leads to a Decision, whether to act and what action to take. Finally, the actions of the decision will lead to Patient Outcomes which are the basis of further monitoring and reasoning. Note, while the information gathering and assessment of goals of treatment are critical to planning treatment. They are separated here to define the process more succinctly. Fig. 3 . This schematic includes a practitioner who is the only practitioner in this scene and who directly influences patient care. This practitioner is faced with n factors that form the basis of clinical reasoning. These are each weighted by n judgements, which are then collated into an overall judgement which leads to a decision that weighs benefits and risks to affect patient care.
for clinical decision making is to reduce the risk of harm to the patient. During the latter half of the 20th century, the goal of risk reduction typically resulted in pharmacists emphasising services as dispenser and clinical checker. With this goal orientation, the pharmacist would dispense a medicine on receipt of a prescription from a prescriber (such as a medical doctor). This role would include clinical checking, where the safety of the prescribed order for medicines is assessed in terms of dose, contraindications, drug interactions, potential for side effects and other clinical drugrelated issues. Since the pharmacist was not necessarily aware of the primary diagnosis, or underlying conditions and comorbidities, it was not possible for these roles to include a beneficent component. The ability to do good, therefore, is conditioned on the knowledge of what good needs to be done. Since 2e40% of prescriptions are purported to contain some form of an error, 9, 10 of which approximately 0.5% (of the total) are considered clinically serious 9 then this role of reducing the risk of (unintended) maleficence is of high importance. In this setting, the medical practitioner (we are considering the prescriber to be a medical practitioner at this point) contributes primary beneficence by initiating the prescription, and the pharmacist is in a nonmaleficent role when they check the prescription. Both the medical practitioner and pharmacist make an independent set of clinical judgements. The role in clinical decision making of each participant is shown schematically in Fig. 4 . Each professional has a different set of information from which to initiate the reasoning processes, and this is shown in Fig. 4 to illustrate the differing sources. For simplicity this is generally omitted in other schematics. In many cases, the non-maleficent practitioner may not know details of the diagnosis or the treatment goals intended by the primary beneficent practitioner. Since there are a number of potential primary beneficent practitioners (including for example, medical practitioners, dentists, nurse practitioners and pharmacists) this paper adopts the term 'primary beneficent practitioner' to denote the practitioner that originates the beneficent activity (in this particular case a prescription). The influence of the non-maleficent practitioner occurs after the primary beneficent practitioner has completed their decision but before patient outcomes have occurred. Here, the pharmacist reduces the potential for harm but does not increase the intended beneficence. Under the assumption that the added risk from the pharmacists intervention is minimal (more on this later), then the risk:benefit ratio will be more favourable since overall maleficence decreases while beneficence does not change. A simple example would be a pharmacist identifying an accidental typographical error in dose and correcting the dosing recommendation. Here, the intended beneficence is not changed, the expected maleficence (i.e. probable side effects at the intended dose) is not changed but the unintended maleficence is averted.
Pharmacists as the secondary beneficent practitioner
In the late 20th century and early 21st century, pharmacists have increasingly taken on clinical service roles. Typically, these Fig. 4 . This schematic depicts two practitioners who act independently of the other but whom intersect at the time of the decision being enacted by the primary beneficent practitioner. The decision from the non-maleficent practitioner (e.g. a pharmacist) relates to a potential harm that might occur but does not influence the clinical reasoning of the primary beneficent practitioner (e.g. a medical practitioner) other than potential learning that may occur for future decisions (but not this decision). In this schematic it is shown formally that both the primary beneficent practitioner and non-maleficent practitioner have access to information, but not necessarily the same information. The goal of the nonmaleficent practitioner is to reduce the risk of harm. services involve the management and optimisation of a patients' medicines regimen. These services span a considerable diversity of clinical interventions that include interventions based on health literacy, adherence support, and medicines optimisation. The key divergence from previous services lies in the pharmacist's access to information about the patient's clinical condition, including diagnosis and the results of common investigations. Access to this information allows pharmacists to act beneficently in a fee-forservice role.
The overarching goal of these clinical services is to improve health outcomes by optimising the healthcare choices of another practitioner (typically a medical practitioner). In this circumstance, we define this complementary role as secondary beneficence. The role cannot exist without a primary beneficent practitioner. In the secondary-beneficent approach, the objective of the practitioner is to augment the decision process or outcomes of the decision of the primary beneficent practitioner. In some cases, this complementary role will happen independently of the primary beneficent practitioner. For example, when a pharmacist provides an adherence support service this increases the therapeutic benefits by enhancing the patient's behaviour towards their healthcare. Whereas in other cases, the objective will be to enhance the primary beneficent practitioner's access to appropriate information that will influence their clinical reasoning and potentially change the treatment options. In this situation, the change occurs by informing the reasoning of the primary beneficent practitioner which then filters through to a potentially revised decision, conditioned on how the information is judged. A typical example would be a medicines optimisation review of a patient's medicines by a pharmacist that yields a change in the decision to prescribe medicine(s). A schematic of secondary beneficence is shown in Fig. 5. 
Pharmacists as the co-beneficent practitioner
Another step in the emergence of pharmacist-led clinical services lies in their shift to a co-beneficent orientation. A typical example is the pharmacist who works in a primary care setting alongside the medical practitioner and they share prescribing roles. Here each takes a lead in different clinical circumstances. Other examples include pharmacist-led clinics in which a medical practitioner may refer a patient for treatment. The co-beneficent role of the pharmacist is depicted schematically in Fig. 6 . In the fully collaborative role, the pharmacist and medical practitioner work in a partnership to arrive at a common healthcare decision that is then enacted. This differs from previous scenarios where the medical practitioner arrives at the decision alone. Services that involve collaborative decision making partnerships allow both practitioners to optimise their beneficent contribution to a patient's healthcare. In the schematic, the width of each arrow is not intended to show equivalent input by each practitioner only. It is possible that one of the practitioner's roles may predominate, such as when a patient is referred to a practitioner-led clinic. In all of these scenarios the beneficent roles of each practitioner formally recognises the know-how of the other practitioner and together they share the decision making process.
Fully independent roles risk marginalising the contribution from each practitioner and can result in a loss of awareness of each other's profession's know-how. We therefore contend that any purely primary beneficent role is not a desirable outcome and will reduce health outcomes of patients.
In the case of pharmacy, a fully independent primary beneficent role, while possible, is only plausible in a specific range of circumstances. We explore the relationship between pharmacy and primary beneficence more in the next scenario, Pharmacists as the primary beneficent practitioner. Historically, pharmacy and medicine have existed a unidirectional relationship. If medicine did not diagnose and prescribe then pharmacists would not have a role in dispensing. Other healthcare professions do not hold such intertwined historical relationships with one another. For example, dentistry can continue to operate in a functional capacity largely with or without the presence of medical practitioners. Contemporary, clinical practice, now strives for collaborative health teams (see for example the review of Jansen). 11 This, with the refocussing of pharmacy from non-maleficent to beneficent scopes, means that these historic unidirectional relationships are no longer viable.
Pharmacists as the primary beneficent practitioner
The authors contend that a primary beneficent service is one in which the practitioner independently diagnoses in order to arrive at a prognosis that is conditioned on an intended treatment plan Fig. 5 . In this schematic a multi-layered approach is considered. The primary beneficent practitioner (e.g. a medical practitioner) is the same as Fig. 4 , but, we see that one of the factors related to clinical reasoning now arises from another practitioner (e.g. a pharmacist). The pharmacist is enacting beneficence through the medical practitioner and so this is termed secondary beneficence. In this figure, the information available to each practitioner is suppressed as it is (in theory) allowable that each practitioner has access to the same information.
that can be initiated by the practitioner. This type of service is not new to pharmacy, particularly in relation to treatment of minor ailments. In this circumstance, the treatment options generally lie in the recommendation of a product, that can be purchased overthe-counter, to the patient. A large component of this role is to rule out non-minor ailments via a triage-like process and hence this role is a combination of minimising unintended maleficence while balancing expected maleficence (i.e. side effects) versus expected beneficence (i.e. treatment benefits).
More recently, pharmacist prescribing has arisen that encompasses a range of collaborative models of care. These roles are essentially primary beneficent in nature and include a diagnostic component, for instance hypertension clinics where pharmacists diagnose and treats hypertension. 12 The framework provided in Fig. 3 provides an understanding of the clinical decision process for pharmacists offering this type of service. It should be recalled, however, that ultimately the patient is more complicated than is necessarily addressed in a single specialty service and hence even here the pharmacist and medical practitioner are operating in a cobeneficent relationship. Healthcare and education both recognise the need for collaborative teams in order to optimise health outcomes.
13e15 It is likely, therefore, that fully independent beneficent practitioner roles are part of an outdated model. However we recognise the not every health care activity will necessarily be shared and hence, health activities are likely to fall on a continuum bounded by strongly cobeneficent and strongly primary beneficent depending on the clinical picture and practice setting.
Implications for pharmacy profession and for pharmacy educators?
There are challenges ahead for pharmacy and for those who educate future pharmacists. Perhaps the most important challenge for pharmacists is one that has received little attention in the pharmacy literature. This challenge involves a reorientation of service roles from non-maleficence to beneficence. As discussed in the previous four sections, how the profession achieves its goals, the skills required, and the educational underpinnings, will be fundamentally different according to its philosophical-orientation.
With a non-maleficent orientation, the primary focus is for pharmacists to reduce adverse drug reactions and medicines errors (see for example Mangino 16 ). With this orientation, a medical practitioner determines the need for medical intervention and informs the health team by invoking a prescription. The prescription is then checked and dispensed by a pharmacist who reviews the order for potential risk. The pharmacist's non-maleficent service biases the risk:benefit analysis away from risk, thereby embracing safety for the patient and the practitioner. If, however, no clinical check is made (perhaps the prescription is filled by an automaton or there are no pharmacy services) then the medical practitioner provides the beneficent service and the maleficent risk remains unabated by the pharmacist. When considering the maleficent component of any beneficent service it is useful to divide this into sources of risk.
Total maleficence risk ¼ expected maleficence þ unintended maleficence Fig. 6 . This setting illustrates a co-beneficence behaviour in which two practitioners (e.g. a medical practitioner and a pharmacist) contribute to a joint decision toward a common patient goal and outcome. It shows that both practitioners have access to the same information from which they draw their own reasoning and independent judgements. The practitioners then collaborate on a joint decision that weights their overall judgements.
Here, expected maleficence encompasses the predictable risks attached to any healthcare intervention (for example the risk of a de-novo allergic reaction). All healthcare interventions carry a risk of side effects. While side effects are not desirable, they are considered as expected at a given probability level and are incorporated into the primary beneficent practitioners risk:benefit assessment. In this case, the risk:benefit is calculated along the following lines. (Note the expresion is inverted to make values greater than 1 represent a net benefit.)
benefits : risks ¼ expected beneficence expected maleficence
It is noted that unintended maleficence is not part of this construct.
Here, the authors consider that unintended maleficence arises from two sources (1) maleficence caused by the primary beneficent practitioner (e.g. a dosing error on a prescription) and (2) maleficence caused by the non-maleficent practitioner (e.g. a dispensing error). With the assumption that the non-maleficent practitioner partially or completely eliminates source (1) and that source (2) is negligible (relative to source 1) then the philosophical framework suggests that services provided by the pharmacist will not be required to focus on their own maleficent risk associated with a clinical checking intervention. They are required, however, to focus on process errors and root-cause analyses that surround the technical role of dispensing. The clinical checker and dispenser roles of the pharmacist have historically been assigned to a single person. However, the clinical decision making processes are different. The clinical checker is the true non-maleficent practitioner and has relatively limited capacity to invoke additional unexpected maleficence. The dispenser, however, has a greater capacity for invoking error and associated harms. Separating these roles and their educational underpinnings, has occurred by introducing checking technicians. 17 Evidence suggests that technician-checkingtechnician is comparable to pharmacist-checking-technician. The establishment of the role of the checking technician has provided a great opportunity to optimise how practitioners improve healthcare outcomes. It is important to recognise that while checking technicians comes at an improved cost-efficiency of service, this is a side effect of the separation process rather than the primary goal.
Newer roles for pharmacists, such as medicines optimisation and pharmacist prescribing require pharmacists to adopt secondary beneficence or co-beneficence roles, respectively, in healthcare. These roles also carry the accompanying risk of maleficence. For example, increasing the intensity of care, by individualising care, while improving beneficence, may well increase the risk of side effects. This will also be accompanied by an increase in unintended maleficence since each additional practitioner involved in the beneficence workflow increases the opportunity for error. Ultimately, it is impossible to augment benefits without increasing the potential for risk as every benefit carries at least some potential risk.
For a profession that has been reared on a risk-averse diet, these new roles signal a change in the operating conditions of the profession. These new roles require a fundamental reconceptualisation of how the pharmacist practitioner contributes to a patients' healthcare. For many practicing pharmacists, an approach to patient care that involves the notion that to do good will risk harm will be in conflict with their current risk adverse approach.
The next challenge for the profession, and particularly for pharmacy educators, is recognition that clinical decision making processes will differ in non-maleficent, secondary beneficent, and co-beneficent settings. (We omit primary beneficent services as these are essentially a special case of a single practitioner version of the co-beneficent framework.) Therefore, the skills that underpin decision making, particularly the tacit reasoning processes that allow a pharmacist to reach a patient-centred decision, will also be different. The term 'clinical reasoning' is used in other health professions interchangeably with 'clinical judgment', 18 'problem solving', 19, 20 'clinical decision making', 21 and 'critical thinking' 22 ; however, this paper differentiates these processes. The clinical decision making process touches on all of these elements but is arguably broader in scope. Clinical decision making is an advanced cognitive skill that allows a practitioner to integrate reasoning processes (i.e., the ability to think through a problem) with their knowledge-base and experience to best meet the needs of an individual patient. Clinical decision making is therefore an essential skill for modern pharmacy practice but is relatively underdeveloped in pharmacy education compared to medicine (see for examples 23e25 ) and other health professions. 26, 27 In pharmacy education, models tend to focus on the practical application of clinical decision making 20,28e30 rather than the hidden cognitive processes that underpin the decisions that are made. The educational aspects of clinical decision making require separate consideration that is beyond the scope of this work.
Conclusion
This paper proposes a philosophical framework for pharmacy. In doing so, it signals the need for a re-evaluation of the skills and knowledge that pharmacists need in order to be able to fill their current and growing future roles. We highlight five fundamental issues that affect the profession and its underpinning educational capacity.
1. Clinical decision making is at the heart of all modern practices of pharmacy practice. 2. Most modern pharmacy professional activities have arisen from a non-maleficent service orientation. 3. Developing and expanding pharmacy professional activities (e.g. fee-for-service clinical consultation, prescribing) require a secondary beneficent or co-beneficent role orientation. 4. The underpinning clinical decision making processes and tools will look different between services with non-maleficent and secondary-or co-beneficent orientations. 5. The profession and those who educate pharmacists need to develop clear mechanisms to support and develop these clinical decision making processes in current practitioners and future pharmacists.
Pharmacy has transformed itself a great deal over the last 500 years. This change is reflected in a transition from the manufacture and sale of a range of bespoke 'pseudo-medicinal' products to a range of fully clinical services. Despite this transition, the range of current pharmacy services remains remarkably broad and includes dispensing, clinical checking, as well as medicines optimisation and prescribing. No single bioethical principle or educational approach can prepare pharmacists for this range of practice. Hence, we propose a multifaceted philosophical framework to help conceptualise the nature of the pharmacy profession in the 21st century.
